Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials

Keyphrases

• Clinical Trials 100%
• Ulcerative Colitis 100%
• Creatine Kinase 100%
• Tofacitinib 100%
• Adverse Events 40%
• Psoriatic Arthritis 40%
• Creatine Kinase Elevation 30%
• Placebo 20%
• Rheumatoid Arthritis 20%
• Clinically Significant 10%
• Incidence Rate 10%
• Non-associated 10%
• Change from Baseline 10%
• Inflammatory Diseases 10%
• Serious Adverse Events 10%
• Maintenance Therapy 10%
• Twice Daily 10%
• Clinical Trial Data 10%
• Trial Registration 10%
• Myopathy 10%
• 2-phase 10%
• Induction Therapy 10%
• Induction Period 10%
• Maintenance Studies 10%
• Maintenance Phase 10%
• JAK Inhibitors 10%
• Long-term Extension Study 10%
• Induction Studies 10%
• Oral Small Molecules 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Ulcerative Colitis 100%
• Creatine Kinase 100%
• Tofacitinib 100%
• Adverse Event 50%
• Placebo 20%
• Rheumatoid Arthritis 20%
• Psoriasis 20%
• Psoriatic Arthritis 20%
• Inflammatory Disease 10%
• Myopathy 10%
• Janus Kinase Inhibitor 10%